New clinical trial uses CAR NK cells derived from human induced pluripotent stem cells (iPSC) as a renewable cell source for product manufacture and off-the-shelf delivery to patients.

Principal Investigator, Veronika Bachanova, MD, PhD, Professor of Medicine at the Medical School and Lead of the Lymphoma Interdisciplinary Team. The multi-centered trial is investigating the safety and activity of the universal, off-the-shelf NK cell product, and builds off of the groundbreaking NK research done by Jeffrey Miller, MD, Deputy Director of the Masonic Cancer Center and Professor of Medicine at the University of Minnesota Medical School.

Read More

Share this post

Related News